ADC Therapeutics Valuation
| ADCT Stock | USD 1.61 0.09 5.29% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. ADC Therapeutics owns a latest Real Value of $3.26 per share. The recent price of the firm is $1.61. Our model approximates the value of ADC Therapeutics from examining the firm fundamentals such as shares outstanding of 96.69 M, and Return On Asset of -0.21 as well as evaluating its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that ADC Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of ADC Therapeutics is based on 3 months time horizon. Increasing ADC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ADC Therapeutics' intrinsic value may or may not be the same as its current market price of 1.61, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.61 | Real 3.26 | Hype 1.64 | Naive 1.55 |
The intrinsic value of ADC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ADC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ADC Therapeutics SA helps investors to forecast how ADC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ADC Therapeutics more accurately as focusing exclusively on ADC Therapeutics' fundamentals will not take into account other important factors: ADC Therapeutics Total Value Analysis
ADC Therapeutics SA is presently forecasted to have valuation of 26.25 M with market capitalization of 164.37 M, debt of 124.38 M, and cash on hands of 376.78 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ADC Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.25 M | 164.37 M | 124.38 M | 376.78 M |
ADC Therapeutics Investor Information
About 21.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.74. ADC Therapeutics recorded a loss per share of 2.39. The entity had not issued any dividends in recent years. Based on the key indicators related to ADC Therapeutics' liquidity, profitability, solvency, and operating efficiency, ADC Therapeutics SA is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.ADC Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ADC Therapeutics has an asset utilization ratio of 19.61 percent. This implies that the Company is making $0.2 for each dollar of assets. An increasing asset utilization means that ADC Therapeutics SA is more efficient with each dollar of assets it utilizes for everyday operations.ADC Therapeutics Ownership Allocation
ADC Therapeutics secures a total of 96.69 Million outstanding shares. Over half of ADC Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.ADC Therapeutics Profitability Analysis
The company reported the previous year's revenue of 69.56 M. Net Loss for the year was (240.05 M) with loss before overhead, payroll, taxes, and interest of (59.85 M).About ADC Therapeutics Valuation
The stock valuation mechanism determines ADC Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of ADC Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of ADC Therapeutics. We calculate exposure to ADC Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ADC Therapeutics's related companies.ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. ADC Therapeutics operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 312 people.
ADC Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as ADC Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 81.7 M |
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.